Companies holding intellectual property in medical products used in the fight against COVID-19 should be aware of formal efforts by a group of nearly 60 developing countries, led by India and South Africa, to obtain a waiver...more
3/5/2021
/ Bilateral Investment Treaties ,
Coronavirus/COVID-19 ,
Diagnostic Tests ,
Foreign Investment ,
Free Trade Agreements ,
Intellectual Property Protection ,
Medical Devices ,
Personal Protective Equipment ,
Prescription Drugs ,
TRIPS Agreement ,
Vaccinations ,
Waivers ,
WTO
The Federal Circuit’s October 2020 split decision in GSK v. Teva made waves throughout the pharmaceutical industry and among Hatch-Waxman litigators. In the broadest reading, some see the majority opinion as rendering any...more